List of Veltassa drug patents
Veltassa is owned by Vifor Pharma.
Veltassa contains Patiromer Sorbitex Calcium.
Veltassa has a total of 13 drug patents out of which 0 drug patents have expired.
Veltassa was authorised for market use on 21 October, 2015.
Veltassa is available in powder;oral dosage forms.
Veltassa can be used as treatment of hyperkalemia.
The generics of Veltassa are possible to be released after 08 October, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 10 days from now) | |
| US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 10 days from now) | |
| US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 10 days from now) | |
| US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 10 days from now) | |
| US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 10 days from now) | |
| US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(1 year, 11 months from now) | |
| US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(3 years from now) | |
| US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(4 years from now) | |
| US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(5 years from now) | |
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) | |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
Market Authorisation Date: 21 October, 2015
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
VELTASSA family patents
63
United States
18
Japan
15
Korea, Republic of
13
European Union
12
Australia
9
United Kingdom
8
Spain
8
China
7
Canada
6
Germany
6
Poland
5
Portugal
5
Brazil
4
Hong Kong
4
Denmark
3
Mexico
3
Lithuania
3
Hungary
2
Croatia
2
Norway
2
Austria
2
Cyprus
2
Slovenia
1
San Marino
1
Luxembourg
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic